CNGB3 and achromatopsia: A recent phase I/II clinical trial of AAV8-hCARp.hCNGB3 gene replacement therapy in adults and children who have CNGB3-associated achromatopsia demonstrated acceptable safety and improvements in several efficacy assessments with 6 months follow-up [14].